VYNDAMAX

Drug Pfizer Inc.
Total Payments
$486,617
Transactions
6,339
Doctors
4,345
Companies
3

Payment Trends by Year

Year Amount Transactions Doctors
2024 $356,030 3,160 2,275
2023 $91,006 2,300 1,845
2022 $38,992 805 643
2021 $575.95 72 49
2020 $6.10 1 1
2019 $6.10 1 1

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $170,947 46 35.1%
Food and Beverage $129,376 5,724 26.6%
Consulting Fee $107,394 27 22.1%
Travel and Lodging $39,689 76 8.2%
Unspecified $27,080 13 5.6%
Space rental or facility fees (teaching hospital only) $9,200 4 1.9%
Education $2,930 449 0.6%

Payments by Type

General
$459,537
6,326 transactions
Research
$27,080
13 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
VYNDAMAX CLINICAL PUBLICATION PROGRAM PFIZER INC. $27,080 10

Top Doctors Receiving Payments for VYNDAMAX — Page 174

Doctor Specialty Location Total Records
, MD Cardiovascular Disease Carolina, PR $2.95 1
, M.D Cardiovascular Disease Newport, KY $2.95 1
, PA-C Physician Assistant Greenville, NC $2.95 1
, M.D Cardiovascular Disease Saint Augustine, FL $2.95 1
, MD Cardiovascular Disease Saratoga Springs, NY $2.95 1
, M.D Cardiovascular Disease Dallas, TX $2.95 1
, MD Family Medicine Cullman, AL $2.93 1
, D.O Nuclear Cardiology Toms River, NJ $2.87 1
, MD Interventional Cardiology Toms River, NJ $2.87 1
Hari Gnanasekeram Philadelphia, PA $2.83 1
, M.D Cardiovascular Disease Weirton, WV $2.64 1
, CRNP Family Decatur, AL $2.57 1
, M.D Nuclear Cardiology Neptune, NJ $2.41 1
, D.O Nuclear Cardiology Brick, NJ $2.41 1
, M.D Family Medicine Pell City, AL $1.96 1
, MD Internal Medicine Overland Park, KS $1.80 1
, MD Family Medicine Pell City, AL $1.70 1
, CRNP Family Pell City, AL $1.70 1
, M.D Internal Medicine Reseda, CA $0.94 2
, FNP-C Student in an Organized Health Care Education/Training Program Richmond, MO $0.74 1
, APRN Family Richmond, MO $0.74 1

About VYNDAMAX

VYNDAMAX is a drug associated with $486,617 in payments to 4,345 healthcare providers, recorded across 6,339 transactions in the CMS Open Payments database. The primary manufacturer is Pfizer Inc..

Payment data is available from 2019 to 2024. In 2024, $356,030 was paid across 3,160 transactions to 2,275 doctors.

The most common payment nature for VYNDAMAX is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($170,947, 35.1% of total).

VYNDAMAX is associated with 1 research study, including "VYNDAMAX CLINICAL PUBLICATION PROGRAM" ($27,080).